NOX
data caveat$20M—
Noxopharm
Biotechnology · Oncology
Senolytic and anti-inflammatory oncology pipeline
Data HealthTrials1 of 1 active · stale enrollment
Cash data from Dec 2025 4CFigures from ASX filings · not financial advice
[ VITALS ]
Cash on Hand
$0.1M
Dec 2025 4C
Runway
—Based on Dec 2025 4C
Market Cap
$20M
Burn Rate
$1.4M/qtr
Dec 2025 4C
Shares Outstanding
307M
Pipeline Assets
3
Latest Insight(1)
27 Feb 2026Half YearAppendix 4D and FY2026 Half Year Financial Report
Cash$0.1M·Burn$2.7M/q·OCF$-2.7M
3M Price
NOX.ASX$0.066-18.5% 3M
Low $0.057High $0.081
Pipeline Assets (3)
SOF-SKNCutaneous lupus erythematosus
Phase 1Veyonda (idronoxil)Soft tissue sarcoma
Phase 1Veyonda (idronoxil)Metastatic castration-resistant prostate cancer
Phase 1/2Discovery
Preclinical
Ph 1
Ph 1/2
Ph 2
Ph 2/3
Ph 3
Capital Raises & Buybacks
show_chart
No capital raise or buyback data
Director Options & Rights
Director
Outstanding
Ex. Price
Expiry
No option data entered yet
Competitive Landscape
7 approved drugs654 competitor trialsPhase 2+ · Non-ASX
Cutaneous Lupus Erythematosus15 active trials
1 Ph46 Ph31 Ph2/36 Ph21 Ph1/PHASE2
Soft Tissue Sarcoma414 active trials
6 Ph442 Ph34 Ph2/3260 Ph2102 Ph1/PHASE2
Approved
Competitor trials from ClinicalTrials.gov (Phase 2+ historical, Phase 3+ refreshed weekly, active/recruiting, non-ASX sponsors). Approved drugs from OpenFDA (NDA/BLA only). Updated weekly via fetch_competitors.py.
Catalysts (8)· 0 upcoming · 8 past
expand_more8 past catalysts
Confirmedarrow_upwardHigh8 Apr 2026
Results available at https://clinicaltrials.gov/study/NCT05100628
Confirmedarrow_upwardHigh8 Apr 2026
Delivery Consistency Index
Historical delivery and spending consistency — data is limited for recently added companies.
Delivery Consistency Index
Delivery
–Insufficient data
0/3 data points needed
Timeline adherence · phase-adjusted tolerance · recency-weighted · min 3 catalysts
Capital discipline
–Insufficient data
1/2 data points needed
Burn rate stability · stage-adjusted thresholds · runway trend · R&D focus
Outcome quality (positive/negative readouts) reflects the science, not execution — shown above but excluded from the score.
These metrics reflect historical operational data only. They are not predictive of future performance, do not constitute investment advice, and should not be used as the basis for any investment decision.
⚠ TIMELINE CHANGESCT.GOV · AUTO-DETECTED
These changes were automatically detected by comparing ClinicalTrials.gov records over time. A slipped date means the trial's expected completion moved later; pulled forward means it moved earlier.
★ RESULTS
Clinical Trials(1)
1 activeClinicalTrials.gov ↗
Early Ph1RecruitingEnrollment stale · 282d
SOF-SKN 0.25%SOF-SKN 0.5%SOF-SKN 1%
Clinical Trial to Evaluate Safety, Tolerability, and Pharmacokinetics of SOF-SKN in Healthy Participants
Cutaneous Lupus Erythematosus
RandomizedQuadruple Blind18 Years – 64 Years
Primary endpoint Percentage of Target Toxicities after a single treatment
Announcements(9)
description
Half YearPSauto_awesome
Appendix 4D and FY2026 Half Year Financial Report27 Feb 2026
expand_more827KB